Use of infliximab to treat psoriatic arthritis in HIV-positive patients

• Published in: Joint, bone, spine : revue du rhumatisme bone, spine : revue du rhumatisme, 2007-03, Vol.74 (2), p.197-200
• Main Authors: Sellam, Jérémie, Bouvard, Béatrice, Masson, Charles, Rousière, Mickael, Villoutreix, Caroline, Lacombe, Karine, Khanine, Vanessa, Chennebault, Jean-Marie, Leclech, Christian, Audran, Maurice, Berenbaum, Francis
• Format: Article
• Language: English
• Subjects: Adult; AIDS; Anti-HIV Agents - therapeutic use; Anti-Inflammatory Agents - therapeutic use; Antibodies, Monoclonal - therapeutic use; Arthritis, Psoriatic - diagnosis; Arthritis, Psoriatic - drug therapy; Arthritis, Psoriatic - etiology; Drug Therapy, Combination; HIV; HIV Infections - complications; HIV Infections - diagnosis; HIV Infections - drug therapy; Humans; Infliximab; Internal Medicine; Male; Methotrexate; Psoriatic arthritis; Rheumatology; TNF-alpha antagonists; Treatment Outcome
• ISSN: 1297-319X; 1778-7254
• DOI: 10.1016/j.jbspin.2006.05.012

Abstract Psoriatic arthritis in HIV-positive patients is not only severe, but also raises specific treatment challenges, as immunosuppressant and immunomodulating agents may adversely affect both the course of the HIV infection and the risk of opportunistic infections. TNFα antagonists have not been evaluated in patients with HIV infection, which is therefore considered to contraindicate their use. Two HIV-positive patients with psoriatic arthritis unresponsive to methotrexate alone were treated with infliximab (5 and 2 mg/kg, respectively), methotrexate, and antiretroviral drugs. Dramatic improvements in the skin and joint manifestations occurred in both patients. Tolerance was good, after follow-ups of 24 and 50 months, respectively. No opportunistic infections occurred. Viral load remained well controlled and CD4 + T-cell counts stable, although both patients required adjustments in their antiretroviral regimens based on close monitoring of these two parameters. HIV infection classically contraindicates the use of TNFα antagonists to treat refractory inflammatory joint disease. However, exceptions to this rule can be made in carefully selected patients who have exhausted all other treatment options for their joint disease and who respond well to antiretroviral therapy. Potential long-term effects such as opportunistic infections, malignancies, and loss of HIV control need to be evaluated.